Medicare Enrolled
Dr. Nader Javadi, M.D.
Optician · Calabasas, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Javadi from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Javadi?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Javadi
Dr. Nader Javadi is an optician specialist in Calabasas, CA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Javadi performed 65,942 Medicare services across 1,081 unique beneficiaries.
Between the years covered by Open Payments, Dr. Javadi received a total of $23,814 from 83 pharmaceutical and/or device companies across 1079 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in optician. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Javadi is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 2% volume in CA
$23,814 industry payments
Medicare Practice Summary
Medicare Utilization ↗65,942
Medicare services
Top 2% in CA for optician
1,081
Unique beneficiaries
$5
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~3,297 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Nivolumab injection (Opdivo) | 24,500 | $1 | $4 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 11,500 | $0 | $2 |
| Iron sucrose injection (Venofer) An injection of iron sucrose used to replenish iron levels in the body. |
6,700 | $0 | $1 |
| Bevacizumab injection, 10 mg Administration of a 10 mg dose of bevacizumab medication via injection. |
6,500 | $6 | $25 |
| Epoetin alfa injection (Procrit) for anemia An injection of epoetin alfa containing 1000 units for use in patients not on end-stage renal disease (ESRD) dialysis. |
5,320 | $4 | $24 |
| Anti-nausea injection (ondansetron/Zofran) | 2,499 | $0 | $0 |
| Denosumab injection (Prolia/Xgeva) | 2,220 | $3 | $8 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,405 | $0 | $0 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
740 | $8 | $22 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
739 | $26 | $100 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
655 | $8 | $14 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
557 | $59 | $218 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
532 | $104 | $360 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
482 | $119 | $454 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
429 | $14 | $54 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
286 | $12 | $52 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
179 | $1 | $29 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
131 | $0 | $1 |
| Urinalysis, manual A manual laboratory examination of a urine sample to check for various substances and cells. |
104 | $3 | $9 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
96 | $56 | $221 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
75 | $11 | $40 |
| New patient office visit, complex (60-74 min) | 67 | $174 | $650 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
62 | $26 | $118 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
58 | $1 | $3 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
51 | $151 | $487 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
37 | $30 | $106 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
18 | $0 | $1 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
3.1% high complexity
93.3% medium
3.6% routine
Industry Payment Transparency
Open Payments through 2024 ↗$23,814
Total received (2018-2024)
Avg $3,402/year across 7 years
Top 8% in CA for optician
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
83
Companies
1,079
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$21,140 (88.8%)
Other
Charitable contributions, space rental, and other categories
$2,524 (10.6%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$150 (0.6%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$4,455
2023
$4,530
2022
$4,559
2021
$4,057
2020
$1,243
2019
$2,474
2018
$2,496
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$758
AstraZeneca Pharmaceuticals LP
$378
PFIZER INC.
$293
Incyte Corporation
$275
E.R. Squibb & Sons, L.L.C.
$232
Celgene Corporation
$229
Exelixis Inc.
$217
Janssen Biotech, Inc.
$217
Daiichi Sankyo Inc.
$163
Merck Sharp & Dohme LLC
$146
PharmaEssentia USA Corporation
$120
Astellas Pharma US Inc
$115
ABBVIE INC.
$103
Gilead Sciences, Inc.
$93
Karyopharm Therapeutics Inc.
$85
Genmab U.S., Inc.
$81
Lilly USA, LLC
$78
SUN PHARMACEUTICAL INDUSTRIES INC.
$75
EMD Serono, Inc.
$72
ARRAY BIOPHARMA INC
$64
Deciphera Pharmaceuticals Inc.
$61
Bayer Healthcare Pharmaceuticals Inc.
$57
Ipsen Biopharmaceuticals, Inc
$50
Agios Pharmaceuticals, Inc.
$49
Eisai Inc.
$44
SOBI, INC
$43
Myriad Genetic Laboratories, Inc.
$38
Genentech USA, Inc.
$32
Immunocore Limited
$31
Takeda Pharmaceuticals U.S.A., Inc.
$31
Stemline Therapeutics Inc.
$29
Blue Earth Diagnostics Limited
$28
PROGENICS PHARMACEUTICALS, INC.
$27
Adaptive Biotechnologies Corporation
$27
ADC Therapeutics America, Inc.
$26
Boehringer Ingelheim Pharmaceuticals, Inc.
$24
Organon Llc
$23
GlaxoSmithKline, LLC.
$22
TAIHO ONCOLOGY, INC.
$21
Top 3 companies account for 32.1% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$1,741
Novartis Pharmaceuticals Corporation
$1,710
PFIZER INC.
$1,611
E.R. Squibb & Sons, L.L.C.
$1,452
NOVARTIS PHARMACEUTICALS CORPORATION
$1,312
Incyte Corporation
$1,233
Janssen Biotech, Inc.
$1,048
Amgen Inc.
$926
Seagen Inc.
$827
Celgene Corporation
$772
Merck Sharp & Dohme Corporation
$737
Exelixis Inc.
$719
Merck Sharp & Dohme LLC
$676
Astellas Pharma US Inc
$574
Lilly USA, LLC
$563
Genentech USA, Inc.
$550
GlaxoSmithKline, LLC.
$498
Daiichi Sankyo Inc.
$433
Eisai Inc.
$331
Gilead Sciences, Inc.
$315
Karyopharm Therapeutics Inc.
$313
Takeda Pharmaceuticals U.S.A., Inc.
$301
Seattle Genetics, Inc.
$300
GENZYME CORPORATION
$295
Kite Pharma, Inc.
$251
EMD Serono, Inc.
$222
Bayer HealthCare Pharmaceuticals Inc.
$210
Clovis Oncology, Inc.
$195
Bayer Healthcare Pharmaceuticals Inc.
$194
EISAI INC.
$192
Deciphera Pharmaceuticals Inc.
$191
Dendreon Pharmaceuticals LLC
$174
PharmaEssentia USA Corporation
$170
ABBVIE INC.
$160
Dova Pharmaceuticals
$155
Novocure Inc.
$143
Ipsen Biopharmaceuticals, Inc
$123
TerSera Therapeutics LLC
$121
INSYS Therapeutics Inc
$114
Epizyme, Inc.,
$113
AtriCure, Inc.
$111
Genmab U.S., Inc.
$102
ImmunoGen, Inc.
$101
Blueprint Medicines Corporation
$100
Blue Earth Diagnostics Limited
$86
TESARO, Inc.
$81
SUN PHARMACEUTICAL INDUSTRIES INC.
$75
Puma Biotechnology, Inc.
$67
ARRAY BIOPHARMA INC
$64
Regeneron Healthcare Solutions, Inc.
$64
BeiGene USA, Inc.
$63
Myriad Genetic Laboratories, Inc.
$59
Alexion Pharmaceuticals, Inc.
$55
Pharmacyclics LLC, An AbbVie Company
$53
TAIHO ONCOLOGY, INC.
$50
Agios Pharmaceuticals, Inc.
$49
Helsinn Therapeutics (U.S.), Inc.
$46
SOBI, INC
$43
Foundation Medicine, Inc.
$34
MEDIVATION FIELD SOLUTIONS LLC
$33
West Therapeutics Development, LLC
$32
Immunocore Limited
$31
Stemline Therapeutics Inc.
$29
Pharmacyclics LLC, an AbbVie Company
$28
Taiho Oncology, Inc.
$28
PROGENICS PHARMACEUTICALS, INC.
$27
Adaptive Biotechnologies Corporation
$27
ADC Therapeutics America, Inc.
$26
Sun Pharmaceutical Industries Inc.
$26
Boehringer Ingelheim Pharmaceuticals, Inc.
$24
SANOFI-AVENTIS U.S. LLC
$24
Organon Llc
$23
Sirtex Medical Inc
$23
MorphoSys, US Inc.
$22
Mylan Pharmaceuticals Inc.
$20
Mylan Institutional Inc.
$20
Heron Therapeutics, Inc.
$19
Mirati Therapeutics, Inc.
$19
Kyowa Kirin, Inc.
$18
PUMA BIOTECHNOLOGY, INC.
$15
Janssen Pharmaceuticals, Inc
$13
Rigel Pharmaceuticals, Inc.
$11
GE HEALTHCARE
$9
Top 3 companies account for 21.3% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AKYNZEO · ALIMTA · ALUNBRIG · AYVAKIT · Abraxane · Alecensa · Aranesp · Avastin · Axumin · BALVERSA · BAVENCIO · BESREMI · BOSULIF · BRUKINSA · Bavencio · Blincyto · CABOMETYX · CYRAMZA · Cabometyx · DARZALEX · Doptelet · ELAHERE · ELITEK · ELREXFIO · EMPLICITI · ENHERTU · ERBITUX · ERLEADA · Elahere · Enhertu · Epi-Sense Guided Coagulation System with VisiTrax · Epkinly · Erleada · FASENRA · FASLODEX · FOUNDATIONONE · FRUZAQLA · Fulphila · GAVRETO · GILOTRIF · Halaven · IBRANCE · IMBRUVICA · IMFINZI · INLYTA · Imbruvica · JAKAFI · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KIMMTRAK · KISQALI · KRAZATI · Kadcyla · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LYNPARZA · Lenvima · MEKINIST · MONJUVI · MVASI · MYCHOICE CDX · MYLOTARG · MYRISK · Models · NERLYNX · NINLARO · Nerlynx · Neulasta · Nexavar · Nplate · Nubeqa · ONTRUZANT · ONUREG · OPDIVO · OPDUALAG · Ogivri · Oncology · Onivyde · Orserdu · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · POSLUMA · PROVENGE · PYLARIFY · PYRUKYND · Perjeta · Pomalyst · QINLOCK · Quzyttir · REBLOZYL · RETACRIT · RYBREVANT · Rubraca · SANCUSO · SANDOSTATIN · SARCLISA · SIR-Spheres Microspheres · SPRYCEL · SUTENT · SYNDROS · Somatuline Depot · Stivarga · Subsys · Sustol · TABRECTA · TAGRISSO · TALZENNA · TAZVERIK · TECENTRIQ · TECVAYLI · TIVDAK · TUKYSA · Tavalisse · Tazverik · Tecentriq · Trodelvy · Ultomiris · VENCLEXTA · VERZENIO · VONJO · Vitrakvi · XALKORI · XGEVA · XOSPATA · XPOVIO · XTANDI · Xermelo · Xospata · Xtandi · YONSA · ZEJULA · ZOLADEX · ZYTIGA · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (89%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians. Total industry engagement is in the top 8% for optician in CA.
Geographic Context
Opticians within 10 mi
1,074
Per 100K population
10.9
County median income
$87,760
Nearest hospital
KAISER FOUNDATION HOSPITAL - WOODLAND HILLS
4.9 mi
4.9 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Javadi is a mixed practice specialist, with above-average Medicare volume (top 2% in CA), with low-engagement industry engagement in the top 8% of CA peers, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Javadi experienced with nivolumab injection (opdivo)?
Based on Medicare claims data, Dr. Javadi performed 24,500 nivolumab injection (opdivo) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Javadi receive payments from pharmaceutical companies?
Yes. Dr. Javadi received a total of $23,814 from 83 companies across 1,079 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Javadi's costs compare to other opticians in Calabasas?
Dr. Javadi's average Medicare payment per service is $5. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Javadi) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Opticians in Calabasas
Browse opticians in Calabasas ranked by procedure volume and transparency data.
Highest volume
Top Opticians in CA
Opticians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Opticians in CA
Which CA opticians receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology